Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2020

View Archived Issues

CAR-T therapy as powerful salvage approach in patients with R/R AL with TP53 alterations

PPARgamma controls antifibrotic network

Viral infection may be second hit for familial ALS

ZBP1 as a new therapeutic target in multiple myeloma

JNJ-7706621 reverses resistance to CD37-targeted radioimmunotherapy in DLBCL

Celgene presents first-in-human data for CC-90009

Cadila Healthcare divulges new antimycobacterial compounds

Chiesi Farmaceutici identifies ROCK1 and ROCK2 inhibitors

BioTheryX presents new compounds for cancer

Chemrar Research & Development Institute discloses dopamine D2 and D3 receptor agonists

New muscarinic M1 receptor antagonists presented by Pipeline Therapeutics

Durect discontinues development of DUR-928 for psoriasis

Opiant signs letter of intent with NCATS to collaborate on OPNT-004 development

Novel copy number genetic variants identified in Diamond Blackfan anemia

Orphazyme reports new data and analysis supporting arimoclomol in NPC

Phase III GRAVITAS-301 study of itacitinib in treatment-naive GvHD misses primary endpoint

Civi Biopharma studies PCSK9 inhibitor CIVI-007 in phase IIa study

Novan reports topline efficacy data from phase III B-SIMPLE program of SB-206 for molluscum

Glutamine transporter variant identified as new cancer target

Taiwan FDA approves Lumosa's IND for LT-5001 for uremic pruritus

Sol-Gel initiates phase I study of SGT-210 in punctate palmoplantar keratoderma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...